
    
      The primary endpoint of this study is the pathological complete response after neo-adjuvant
      Erbitux-based chemotherapy followed by surgery and radiotherapy. The second endpoint of this
      study is the disease free survival rates (1, 2, 3, 5 years), locoregional control rates (1,
      3, 5 years), overall survival rate (3, 5 years), and the safety.
    
  